CDC42 and breast cancer: We found that BLBCs inhibit activity of the RFC pathway via Cdc42 and that restoring activity of this pathway by genetic or pharmacological inhibition of Cdc42 enables the pro-oxidant activities of low μM concentrations of TMX to be harnessed so as to have multiple beneficial effects on BLBCs, one of the most dangerous categories of breast cancers.